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sInsights & PerspectivesDNA methylation reprogramming in
cancer: Does it act by re-configuring
the binding landscape of Polycomb
repressive complexes?
James P. Reddingtony, Duncan Sproul and Richard R. Meehan*DNA methylation is a repressive epigenetic mark vital for normal development.
Recent studies have uncovered an unexpected role for the DNA methylome in
ensuring the correct targeting of the Polycomb repressive complexes
throughout the genome. Here, we discuss the implications of these findings for
cancer, where DNA methylation patterns are widely reprogrammed. We
speculate that cancer-associated reprogramming of the DNA methylome leads
to an altered Polycomb binding landscape, influencing gene expression by
multiple modes. As the Polycomb system is responsible for the regulation
of genes with key roles in cell fate decisions and cell cycle regulation,
DNA methylation induced Polycomb mis-targeting could directly drive
carcinogenesis and disease progression.cancer epigenetics; DNA methylationKeywords:; epigenomics; H3K27me3; Polycomb;
reprogrammingIntroduction
Epigenetic systems modulate the in-
terpretation of the information con-
tained in genomes by regulating DNA.201300130
Unit, MRC IGMM,
h, Edinburgh, United
nome Biology Unit,
iology Laboratory,
.
or:
@igmm.ed.ac.uk
ys-journal.com Bioessays
open acce
distributiondependent processes. Many different
epigenetic pathways act in mammalian
cells and recent work has highlighted
extensive interactions between them
[1]. The epigenome is frequentlyAbbreviations:
CGI, CpG island; CpG, cytosine followed imme-
diately by a guanine in the 50 to 30 direction; ES,
embryonic stem (cells); H3K27me3, tri-methyla-
tion of lysine 27 on histone H3; hmC, 50-hydroxy-
methylcytosine; LINE, long interspersed nuclear
element; mC, 50-methylcytosine; MEFs, mouse
embryonic fibroblasts; PMDs, partially (DNA)
methylated domains; PRC, Polycomb repressive
complex; PRC1, Polycomb repressive complex 1;
PRC2, Polycomb repressive complex 2.
36: 134–140, 2013 The Authors. Bioessays pu
ss article under the terms of the Creative Comm
and reproduction in any medium, provided the oaltered in cancer, and there is evidence
to suggest that interactions between
distinct epigenetic mechanisms are
important drivers in this process [2,
3]. Identifying the causes of epigenetic
reprogramming in cancer and under-
standing its consequences for disease
pathology are key challenges in mo-
lecular biology.
DNA methylation and the Polycomb
repression system are two epigenetic
pathways that play key roles in cancer
formation and progression. Here, we
focus on recent evidence that links DNA
methylation to the genomic targeting
of Polycomb repressive complexes
(PRCs), the effectors of the Polycomb
system. In light of this evidence, we
discuss how widespread reprogram-
ming of DNA methylation patterns in
cancer could drive the relocation of
PRCs on chromatin, and contribute to
carcinogenesis through alterations in
gene expression.The cancer DNA
methylome: How does it
change and what are the
consequences?
Mammalian genomes exhibit wide-
spread DNA methylation that is ac-
quired during early development [4].
DNA methylation is laid down and
maintained by the DNA methyltransfer-
ases, DNMT1, DNMT3A, and DNMT3B,blished by WILEY Periodicals, Inc. This is an
ons Attribution License, which permits use,
riginal work is properly cited.
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Figure 1. Reprogramming of DNA methylation patterns in cancer. Frequently observed
changes to the DNA methylome in cancer are depicted for a portion of a hypothetical
genome. CpG dinucleotides are depicted as open (unmethylated cytosine) or filled
(5-methylcytosine). In healthy somatic cells (“Normal DNA methylome”) the background level
of CpG methylation throughout the bulk genome is high, while CGIs are infrequently
methylated [5, 28]. In cancer, CGIs frequently become hypermethylated (red bars and
boxes), and CpG methylation is reduced across large genomic domains (blue bars and
boxes) [14, 16]. Focal CGI hypermethylation frequently occurs within larger hypomethylated
domains [16]. Only unmethylated and 5-methylcytosine are shown for simplicity. CGI, CpG
island.
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sand generally occurs at cytosines in a
50-CG-30 (CpG) dinucleotide context [4].
This pervasively methylated landscape
is interspersed with short hypomethy-
lated regions, the best described of
which are CpG islands (CGIs) [5]
(Fig. 1). Enzymes of the TET family
can oxidize methylated cytosine (mC)
to generate further modified bases,
of which 50-hydroxymethylcytosine
(hmC) is the most abundant [6]. The
oxidation of mC by TET enzymes
is proposed to be the first step in
DNA demethylation pathways but
stable levels of hmC of unknown
significance are found in the bodies
of active genes [6].
DNA methylation is classically im-
plicated in gene regulation at pro-
moters, where it is proposed to
repress transcription initiation by atten-
uating the binding of transcription
factors, and recruiting repressor
complexes through the attraction of
methyl-CpG binding proteins [7]. CGIs
rarely become methylated during nor-
mal development and most are likely
to function as gene promoters [5].
However, the methylation of some CGIs
plays a vital role in genomic imprinting,Bioessays 36: 134–140, 2013 The Authors. Bthe inactivation of one copy of the X
chromosome in female cells and
the regulation of some tissue-specific
genes [4].Cancer DNA methylomes
exhibit focal
hypermethylation and
widespread
hypomethylation
Two radical differences exist between
normal mammalian DNA methylation
landscapes and those found in cancer:
many CGIs become aberrantly hyper-
methylated in cancerous cells, and
large amounts of DNA methylation
are lost from other genomic regions [8]
(Fig. 1). Interestingly, the Polycomb
system has been suggested to play an
instructive role in the hypermethyla-
tion of promoter DNA in cancer, as
genes that are subject to promoter
hypermethylation are frequently
marked by PRC2-deposited H3K27me3
in early development [2, 9, 10]. Hyper-
methylation of CGI promoters wasioessays published by WILEY Periodicals, Inc.classically believed to directly drive
carcinogenesis by silencing tumor
suppressor genes [8]. Studies using
genomic profiling technologies have
conclusively demonstrated that this
is not the case for the vast majority
of aberrantly hypermethylated genes,
as they are already silenced in
the corresponding normal cells that
give rise to cancer [11–13]. However,
these observations do not rule out
the possibility that rare driver genes
are directly silenced by aberrant CGI
hypermethylation [11].
In addition to aberrant CGI hyper-
methylation, cancer genomes exhibit
widespread loss of DNA methylation
(Fig. 1). Work over many years sug-
gested that loss of methylation occurs
primarily in the repetitive portion
of the genome, in particular satellite
repeats and LINE-1 retrotranspo-
sons [14]. This view has been radically
altered by the application of whole
genome bisulfite sequencing technolo-
gy to cancer, which revealed that DNA
methylation is lost frommegabase-scale
genomic domains [3, 15, 16]. Although
these domains are enriched in LINE-1
elements, those lying outside of these
domains do not become hypomethy-
lated, suggesting that the loss of
methylation is not specific to retro-
transposons [14, 15]. Hypomethylated
domains often overlap with other fea-
tures of mammalian genomes, particu-
larly lamin-associated domains, which
associate with the nuclear lamina at
the periphery of the nucleus [14, 16].
However, it is currently unclear whether
the nuclear lamina is mechanistically135
Box 1 – Polycomb repressive complexes and their
genomic targeting
The Polycomb system is a highly conserved epigenetic mechanism that
contributes to the stable repression of thousands of target genes outside of
their normal expression domains [40]. The system comprises the coordinated
action of several multi-protein complexes that associate with chromatin, many
of which chemically modify histone proteins through the deposition of histone
marks. The Polycomb Repressive Complex 2 (PRC2) catalyses tri-methylation
of lysine 27 on histone H3 (H3K27me3), a signature of repression mediated by
this complex. A subset of Polycomb repressive complex 1 (PRC1) binds to the
H3K27me3 mark and catalyses the mono-ubiquitination of histone H2A. A
major question in Polycomb research is how PRCs are targeted to the correct
genomic compartments [40]. Polycomb targeting is best understood in the
fruit fly, where PRCs are recruited to specific sequence elements called
Polycomb response elements (PREs) by combinations of sequence-specific
binding proteins [40]. PRC recruitment is far less understood in mammals and
is thought to result from the interaction between multiple DNA sequence
features and chromatin structure [40]. For example, CGIs have been linked to
the recruitment of Polycomb complexes [36], but the mechanism of
recruitment to these elements remains unclear.
J. P. Reddington et al. Insights & Perspectives.....
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sconnected to the loss of methylation
in cancer.
Experiments in transgenic animals
have demonstrated that genomic hypo-
methylation can either inhibit or pro-
mote carcinogenesis depending on the
cellular context [17, 18]. Loss of DNA
methylation causes genomic instability
in transgenic animals [17], cultured
cells [19], and in patients with Immu-
nodeficiency–Centromeric instability–
Facial anomalies (ICF) syndrome, which
is caused by mutations in DNMT3B [20].
Hypomethylation may also promote
cancer by potentiating the activation
and transposition of LINE-1 ele-
ments [21]. Such activation can poten-
tially directly disrupt genes through
transposition into their vicinity [22, 23]
or because transcription from LINE-1
promoters can affect neighboring
genes [24, 25].
Despite the application of the latest
genomic approaches to cancer DNA
methylomes, we still have a limited
understanding of the causes of DNA
methylation reprogramming and its
impact on cancer phenotypes. The
picture is complicated by heterogeneity
caused by differences in cellular origin
or stochastic clonal evolution [12]. Fur-
thermore, recent studies seeking to
understand the role of DNAmethylation
in normal cells have uncovered previ-
ously unappreciated functions of the
DNA methylome in gene regulation,
highlighting the diverse ways that this
epigenetic mark is utilized in mammali-
an genomes [1].A new role for DNA
methylation in shaping the
Polycomb landscape
In addition to methyl-CpG binding
proteins, we now know that an eclectic
variety of proteins exhibit DNA methyl-
ation-modulated binding to chroma-
tin [1, 26]. Many of these possess
histone-modification activity, and are
involved in setting up diverse aspects of
chromatin organization, highlighting
roles for DNA methylation outside of
promoter proximal regions [1]. This
raises the possibility that the effects of
an altered DNA methylome in cancer
could be more widespread than current-
ly appreciated.136DNA methylation
attenuates PRC2 binding
to chromatin
It has emerged that DNA methylation
plays an unexpected role in restricting
the genomic targeting of Polycomb
repressor complexes (PRCs) (see Box 1
for an overview of Polycomb repressive
complexes and their targeting). While
DNA methylation and Polycomb were
once considered to be two independent
and complementary pathways of tran-
scriptional repression, it is now con-
ceivable that direct cross talk occurs
between them. Epigenome profiling
experiments showed that high levels
of DNA methylation and H3K27me3
are rarely found at the same loci in
mammalian genomes, suggesting
that the presence of one mark is
antagonistic to the other [27–32]. This
relationship is most prominent at
CGIs [31], but can be observed to a
lesser extent at large partially methylat-
ed domains (PMDs) in cultured cells [28,
30]. Exclusivity between the two marks
is exemplified by the imprinted Rasgrf1
locus where one allele is marked by
DNA methylation and the other by
H3K27me3 [33].
Recent studies have addressed the
cause-consequence relationships in-
volved in establishing these patternsBioessays 36: 134–140, 2013 The Authors. Bioby perturbing either DNA methylation
or H3K27me3 and asking what happens
to the other mark. Inmultiple organisms
and experimental systems, the removal
of DNA methylation has a profound
influence on the distribution of the
H3K27me3 mark throughout the ge-
nome [29, 31, 33–37]. Crucially, removal
of DNA methylation results in accumu-
lation of the PRC2 complex and
H3K27me3 in illegitimate genomic loca-
tions that were previously DNA methyl-
ated [31, 34, 35], suggesting that dense
DNA methylation is capable of attenu-
ating PRC2 binding to chromatin. This is
supported by in vitro experiments
demonstrating reduced PRC2 occupan-
cy and activity on DNA methylated
chromatin templates [26, 34]. In addi-
tion, TET1 is required for a significant
proportion of PRC targeting in mouse ES
cells, connecting this putative demeth-
ylation pathway to PRC recruitment [38].
In contrast, when PRC2 components are
removed only modest changes in DNA
methylation are observed [39], suggest-
ing that the H3K27me3 mark does not
have a similar reciprocal effect on the
placement of DNA methylation in non-
transformed cells.
While the majority of studies have
focused on the influence of DNA
methylation on the PRC2 complex, it
is likely that PRC1 localization is
also affected. Canonically, PRC1 isessays published by WILEY Periodicals, Inc.
..... Insights & Perspectives J. P. Reddington et al.
Id
e
a
s
&
S
precruited to genomic loci by the
H3K27me3 mark laid down by
PRC2 [40], so restriction of PRC2
binding by DNA methylation would
be expected to also affect PRC1 recruit-
ment. A recent study has also detailed
a non-canonical PRC1 recruitment
pathway mediated by the KDM2B
protein, which contains an unmethy-
lated CpG binding CXXC domain [41]. e
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u
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sThe DNA methylome is
required for correct PRC2-
mediated gene repression
As PRCs are involved in transcriptional
repression, their redistribution upon
loss of DNA methylation can have
significant effects on the transcriptome.
For example, in Dnmt3a mutant neural
stem cells, levels of DNA methylation
are reduced within the body of some
actively transcribed genes, leading to
PRC2 binding and repression of their
transcription [34]. Removal of most DNA
methylation from mouse embryonic
fibroblasts (MEFs) leads to a variety
of transcriptional consequences con-
nected to PRC redistribution [35]. Genes
lying within regions of the genome that
accumulate H3K27me3 in DNA methyl-
ation mutants are often transcriptional-
ly down-regulated, consistent with de
novo repression by PRC2 within these
regions [35]. Surprisingly, many normal
PRC2 target genes are de-repressed in
DNAmethylation mutants, concomitant
with loss of H3K27me3 from their
promoter regions [35]. Importantly,
these genes are associated with unme-
thylated CGI promoters in wild type
cells [35], meaning that DNA methyla-
tion would not normally be implicated
in their regulation. The loss of
H3K27me3 observed here could be
explained by dilution of a limited
amount of PRC2, due to the increased
binding of this complex to numerous
intergenic sites uncovered by loss of
DNA methylation [35].
Many interesting questions remain
concerning the relationship between
DNA methylation and the Polycomb
system and its implications for genome
regulation. Despite the fact that in vitro
experiments have suggested that PRC2 is
able to directly read CpG methylation
states [26, 34], themolecularmechanismBioessays 36: 134–140, 2013 The Authors. Bunderlying this cross talk is currently
furtive. One important implication of
these observations is that reprogram-
ming of DNA methylation patterns in
cancer could trigger mis-regulation of
transcriptional programs through sub-
sequent redistribution of the repressive
activity of PRCs.Do DNA methylation
changes drive Polycomb
redistribution in cancer?
In addition to changes in the DNA
methylome, H3K27me3 patterns are
subject to reprogramming in cancer
cells [32, 42]. Studies have documented
correlated changes in DNA methylation
and H3K27me3 in cancer, raising the
possibility that at least some of the
redistribution of these two marks is
causally linked [3, 43].
Based on frequently observed
changes to the DNA methylome in
cancer, multiple putative effects on
PRC-mediated gene regulation can be
envisaged (Fig. 2). One such pathway
is epigenetic switching, where DNA
methylation replaces PRCs at CGIs
in cancer [43] (Fig. 2A). Both studies
of individual genes and epigenomic
profiling have shown that promoter
CGIs that are subject to aberrant hyper-
methylation in cancer are frequently
marked by PRCs during development [2,
9, 10]. In prostate cancer, developmen-
tally important CGI genes silenced
by PRC2 in normal prostate cells
acquire DNA methylation concomitant
with loss of their PRC2 marks [43].
Because these genes are normally
silent in the tissue that gives rise to
cancer, this epigenetic switch would
not be expected to cause de novo
repression. However, as repression by
DNA methylation is more stable than
PRC-mediated repression, this switch
could significantly reduce epigenetic
plasticity by preventing the future
activation of genes in response to
external stimuli, potentially blocking
cellular differentiation [11].
Genomic hypomethylation in cancer
is also likely to impact on the tran-
scriptome. The de novo formation or
exacerbation of PMDs in cancer, due to
the processes underlying hypomethyla-
tion, could uncover binding sites forioessays published by WILEY Periodicals, Inc.PRC2, allowing the formation of new
H3K27me3 domains and causing the
repression of multiple adjacent genes
(Fig. 2B) [3]. The H3K27me3 modifica-
tion is thought to be propagated by the
binding of the PRC2 component EED to
H3K27me3 resulting in spreading of
PRCs unless boundaries are applied
[44]. DNA methylation surrounding a
PRC2-bound locus could act locally to
prevent spreading of H3K27me3 into
neighboring regions (Fig. 2C). Proximity
to existing H3K27me3 marked loci
could, therefore, play an important role
in determining whether a gene becomes
repressed by PRC recruitment following
loss of DNA methylation.
In addition to de novo gene repres-
sion, loss of PRC restriction by DNA
methylation in cancer could paradoxi-
cally result in the de-repression of
Polycomb-target genes, as observed in
DNA methylation mutant MEFs [35]
(Fig. 2D). In support of this hypothesis,
loss of H3K27me3 and de-repression
of PRC targets has been reported in
cancer [45, 46], but it is currently
unclear if these alterations are driven
by cancer-associated hypomethylation.
Such a pathway is most probable in
cancers that exhibit the largest degree of
DNA hypomethylation. However, the
picture is likely to be complicated by
the elevated expression, and frequent
mutation, of Polycomb components
in certain cancers [40, 42]. It has also
been suggested that the relationship
between DNA methylation and PRC2
is fundamentally different in normal
and transformed cells, adding a further
layer of complexity to this problem [29].
The targets of PRCs include a large
number of genes with key functions
in cell lineage decisions and the regula-
tion of the cell cycle [40]. The mis-
regulation of these genes could in
theory have a major impact on the
formation and progression of cancer,
providing the impetus for further re-
search in this area.Conclusions and
prospects
In differentiated cells part of the barrier
to transformation is precise partitioning
of the genome into active and repressed
domains; epigenetic reorganization of137
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Figure 2. Putative pathways for gene mis-regulation in cancer. Previously described and
hypothetical changes to PRC2-mediated gene repression in cancer in response to DNA
methylation redistribution. A: DNA hypermethylation of a PRC2-bound promoter CGI in
cancer causes loss of PRC2 and H3K27me3 [43]. B: The loss of DNA methylation across
large genomic domains could allow PRC2 to form large blocks of H3K27me3 modified
chromatin de novo, leading to the silencing of multiple adjacent genes [3]. C: Loss of DNA
methylation surrounding H3K27me3 marked regions allows spreading of PRC2 occupancy
into adjacent chromatin and de novo gene repression. D: Widespread loss of DNA
methylation throughout the cancer genome allows PRC2 to occupy a large number of new
sites, distributing the complex over a larger proportion of the genome. As a result, PRC2
occupancy is reduced at normal PRC2-target genes, leading to de-repression of a subset of
them that are particularly sensitive to PRC2 reduction [35]. PRC2, Polycomb repressive
complex 2.
J. P. Reddington et al. Insights & Perspectives.....
138 Bioessays 36: 134–140, 2013 The Authors. Bio
Id
e
a
s
&
S
p
e
c
u
la
ti
o
n
sthese domains is a feature of both
cellular and cancer reprogramming.
Understanding the cause and functional
impact of epigenetic reprogramming is a
major goal of both basic and clinical
research. The action of PRCs is funda-
mentally important to many types of
cancers as exemplified by the recurrent
mutations of PRC components uncov-
ered by cancer re-sequencing stud-
ies [14]. Reprogramming of the DNA
methylome in cancer could drive further
epigenetic instability in an unexpectedessays published by WILEY Periodicals, Inc.
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sway, by reshaping the PRC binding
landscape.
The functional consequences of
DNA methylation mediated PRC redis-
tribution as described here are also
likely to be important in other biological
systems. Large-scale hypomethylation
and the formation of PMDs are now
known to be a feature of aging cells [47]
and of some normal cell populations
including the placenta [48] and mature
B-cells [49].
In cancer, this mechanism could
potentially impact genome regulation
in many ways, leading to a transcrip-
tome that facilitates cancer formation,
plasticity, and progression, or influen-
ces how cancers respond to therapy. We
are just beginning to comprehend the
epigenetic heterogeneity that exists in
cancer [14]. Changes to the DNA meth-
ylome driven by a stochastic or step-
wise process could offer a substrate for
cellular Darwinism [14, 50], providing
intermediates with favorable patterns of
gene expression that arise due to altered
H3K27me3 targeting. Future studies
should concentrate on dissecting the
cause-consequence relationships in-
volved, and exploring potential points
of therapeutic intervention.Acknowledgments
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